New data boosts case for extended use of AstraZeneca heart drug
Reuters: Health News
LONDON (Reuters) - AstraZeneca's blood-thinner Brilinta cuts the risk of cardiovascular death by 29 percent in patients with a history of past heart attacks who keep taking it beyond the standard 12-month initial period, according to new clinical trial data.
ZURICH (Reuters) - Novartis AG said its drug Kisqali (ribociclib) received European Union approval as first-line treatment for a tough-to-treat breast cancer, bolstering the Swiss drugmaker's bid to challenge U.S. rival Pfizer's Ibrance.
ZURICH (Reuters) - Swiss pharma group Roche said the U.S. Food and Drug Administration (FDA) granted priority review to its emicizumab for hemophilia A with inhibitors.
No comments:
Post a Comment